Purpose : A clinical trial of intestinal transplantation (ITx) under tarolimus and prednisone immunosuppression was initiated in June 1990 in patients with irreversible intestinal failure, and who were dependent on total parenteral nutrition (TPN)
Methods : Sixty-four patients (33 girls, 31 boys) with a median age of 3.5 years (range, 0.5 to 18 years) received 68 intestinal transplants that included isolated small bowel (SB) (n=19), liver and small bowel (LSB) (n=39), and multivisceral (MV) (n=10) allografts. Indication for Itx included : volvulus (n=18), gastroschisis (n=16), intestinal atresia (n= 8), necrotizing enterocolitis (n= 7), chronic intestinal psuedo-obstruction (n= 6), Hirschprung's disease (n= 4), microvillous inclusion disease (n= 3), multiple polyposis (n= 1), and trauma (n= 1).
Results : Currently 36 patients and 33 grafts are alive. Patient and graft survival at 5-year was 59% and 53%, respectively. Graft survival at 5-year in SB, LSB and MV was 67%, 46%, and 35%, respectively. Five-year graft survival of patients more than 10 years old was 89%. Immunological complications included liver allograft rejection (n=18), intestinal allograft rejection (n=64), and graft-versus-host disease (GVHD) (n=10). Steroid resistant rejection defined as OKT3 administration was more frequent in the patients received SB. Exfoliative rejection occurred in 12 patients and 14 grafts, and of thess 4 patients with 3 grafts survived. Ten grafts were removed because of rejection (n= 7), and because of posttransplant lymphoproliferative disease (PTLD), pancreatitis and hepatic arterial thrombosis, one each. There were five retransplants (SB, n= 1 ; LSB, n= 4), and of these three failed. GVHD was occurred in 10 grafts. Graft loss occurred as a result of rejection (n= 9), PTLD (n = 9), infection (n=7), technical complication (n=6), rejection and PTLD (n = 3), and pancreatitis and unknown cause one each. At present, 94% (31/33 grafts) were functional and was exclusively orally fed.
Conclusions : Intestinal transplantation is a valid therapeutic option for patients with intestinal failure suffaring, and who have complications of TPN. The complex clinical and immunological course of these patients after transplantations reflected in a higher complication rate as well as patient and graft loss than seen after heart, liver, and kidney transplantation, although better than after lung transplantation.
View full abstract